RxDoctor Payments Data

Peter Vlismas, MD

Advanced Heart Failure and Transplant Cardiology · Hartford, CTNPI 1720491384

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,478 of the $1,647 with a category attached, or 89.7%. It is spread thinly across 16 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $488, 2.9 times the $169 reported in 2021.

$1,647in general payments, 2019–2025

Across 56 payments — averaging $29.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$375
  • AstraZeneca$232
  • Medtronic$169
  • Alnylam Pharmaceuticals Inc.$168
  • Boehringer Ingelheim$142
  • Novartis$105
  • plus $456 from 10 others

What the payments were for

  • Grants$16910%
  • Food & beverage$1,47890%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$51,860
Medicare patients
105
Services billed
416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis16$802,312
EntrestoSacubitril/Valsartan60$61,855
JardianceEmpagliflozin46$46,997
FarxigaDapagliflozin Propanediol11$14,355
EliquisApixaban16$11,749
Torsemide57$1,169
Eplerenone17$859
Midodrine Hcl15$629
Metoprolol Succinate43$513
Spironolactone56$433
Losartan Potassium20$265
Potassium Chloride18$140
Atorvastatin Calcium23$130
Furosemide14$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$94$814,06132 claims
NovartisEntresto$105$61,85560 claims
Boehringer IngelheimJardiance$142$46,99746 claims
AstraZenecaFarxiga$232$14,35511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →